Contributions
Abstract: P1914
Type: Poster
Abstract Category: Late breaking news
Background: The regulatory role of interleukin-35 (IL-35) in immunipathogenesis of multiple sclerosis (MS) is suggested in very few studies. We aimed to measure serum levels of IL-35 among clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) patients and evaluate the associations between this cytokine and the disease clinical course.
Methods: This cross-sectional study was conducted during 2017 in MS Clinic of Kashani hospital, Isfahan, Iran. Patients with diagnosis of CIS and RRMS according to McDonald criteria were included in the study, as well as healthy controls. We measured serum levels of IL-35 in all subjects. Also, data regarding clinical course of the disease was collected from cases. We compared IL-35 serum levels between cases and healthy subjects as the study outcome.
Results: The final study population included 28 RRMS, 46 CIS, and 40 healthy subjects, with no statistically significant difference regarding age and sex (P-value>0.05). Serum levels of IL-35 (mean [standard deviation]) between RRMS patient, CIS patients, and healthy controls were 2.62 (1.10), 3 (1), and 3.41 (1.05), respectively (P-value=0.041). The mean serum level of IL-35 among new cases (diagnosed within 6 months before the study) and other cases were 3.01 (1.13) and 2.41 (0.61), respectively (P-value=0.048).
Conclusion: We found an adverse trend between serum levels of IL-35 and the clinical course of the disease, as RRMS patients had the lowest IL-35 levels and healthy controls had the highest levels. We provide a view of the possible role of IL-35 in MS and the potential therapeutic targets in this way.
Disclosure:
Shervin Badihian: nothing to disclose
Omid Mirmosayeb: nothing to disclose
Navid Manouchehri: nothing to disclose
Nafiseh Esmaeili: nothing to disclose
Zahra Samee: norhing to disclose
Vahid Shaygannejad: nothing to disclose
Funding: This work was supported by vice-chancellor for Research and Technology of Isfahan University of Medical Sciences [grant number: 195105].
Abstract: P1914
Type: Poster
Abstract Category: Late breaking news
Background: The regulatory role of interleukin-35 (IL-35) in immunipathogenesis of multiple sclerosis (MS) is suggested in very few studies. We aimed to measure serum levels of IL-35 among clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) patients and evaluate the associations between this cytokine and the disease clinical course.
Methods: This cross-sectional study was conducted during 2017 in MS Clinic of Kashani hospital, Isfahan, Iran. Patients with diagnosis of CIS and RRMS according to McDonald criteria were included in the study, as well as healthy controls. We measured serum levels of IL-35 in all subjects. Also, data regarding clinical course of the disease was collected from cases. We compared IL-35 serum levels between cases and healthy subjects as the study outcome.
Results: The final study population included 28 RRMS, 46 CIS, and 40 healthy subjects, with no statistically significant difference regarding age and sex (P-value>0.05). Serum levels of IL-35 (mean [standard deviation]) between RRMS patient, CIS patients, and healthy controls were 2.62 (1.10), 3 (1), and 3.41 (1.05), respectively (P-value=0.041). The mean serum level of IL-35 among new cases (diagnosed within 6 months before the study) and other cases were 3.01 (1.13) and 2.41 (0.61), respectively (P-value=0.048).
Conclusion: We found an adverse trend between serum levels of IL-35 and the clinical course of the disease, as RRMS patients had the lowest IL-35 levels and healthy controls had the highest levels. We provide a view of the possible role of IL-35 in MS and the potential therapeutic targets in this way.
Disclosure:
Shervin Badihian: nothing to disclose
Omid Mirmosayeb: nothing to disclose
Navid Manouchehri: nothing to disclose
Nafiseh Esmaeili: nothing to disclose
Zahra Samee: norhing to disclose
Vahid Shaygannejad: nothing to disclose
Funding: This work was supported by vice-chancellor for Research and Technology of Isfahan University of Medical Sciences [grant number: 195105].